Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single center, non-randomized, phase I trial to evaluate the safety
and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the
recurrent or metastatic nasopharyngeal carcinoma.